Targeting ECM disrupts cancer progression

Frontiers in Oncology

Volumn 5, Issue OCT, 2015, Pages

  Venning, Freja A ^a   Wullkopf, Lena ^a   Erler, Janine T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Collagen I; Extracellular matrix; Hyaluronan; Metastasis; Periostin; Tenascin C

Indexed keywords

BETA CATENIN; BETA1 INTEGRIN; COLLAGEN TYPE 1; FIBRONECTIN; HERMES ANTIGEN; HYALURONIC ACID; NOTCH RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN LYSINE 6 OXIDASE; PROTEINASE ACTIVATED RECEPTOR 4; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; TENASCIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR TWIST; TRASTUZUMAB; UVOMORULIN; VERSICAN; WNT PROTEIN;

BREAST CANCER; CANCER GROWTH; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

EID: 84947077516     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00224     Document Type: Review

References (147)

1. Sporn MB. The war on cancer. Lancet (1996) 347(9012):1377-81. doi:10.1016/S0140-6736(96)91015-6
2. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer (2009) 9(4):239-52. doi:10.1038/nrc2618
3. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell (2006) 127(4):679-95. doi:10.1016/j.cell.2006.11.001
4. Hynes RO. The extracellular matrix: not just pretty fibrils. Science (2009) 326(5957):1216-9. doi:10.1126/science.1176009
5. Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J (1993) 294(Pt 1):271-8. doi:10.1042/bj2940271
6. Norris RA, Damon B, Mironov V, Kasyanov V, Ramamurthi A, Moreno-Rodriguez R, et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem (2007) 101(3):695-711. doi:10.1002/jcb.21224
7. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell (2004) 5(4):329-39. doi:10.1016/S1535-6108(04)00081-9
8. Tilman G, Mattiussi M, Brasseur F, van Baren N, Decottignies A. Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells. Mol Cancer (2007) 6:80. doi:10.1186/1476-4598-6-80
9. Fukushima N, Kikuchi Y, Nishiyama T, Kudo A, Fukayama M. Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol (2008) 21(8):1044-53. doi:10.1038/modpathol.2008.77
10. Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D'Aurizio F, et al. Expression of periostin in human breast cancer. J Clin Pathol (2008) 61(4):494-8. doi:10.1136/jcp.2007.052506
11. Takanami I, Abiko T, Koizumi S. Expression of periostin in patients with non-small cell lung cancer: correlation with angiogenesis and lymphangiogenesis. Int J Biol Markers (2008) 23(3):182-6.
12. Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Abstract SY28-02: interactions between cancer stem cells and their niche govern metastatic colonization. Cancer Res (2012) 72(8 Suppl):SY28-22. doi:10.7554/eLife.06938
13. Sasaki H, Dai M, Auclair D, Fukai I, Kiriyama M, Yamakawa Y, et al. Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas. Cancer (2001) 92(4):843-8. doi:10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P
14. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat (2003) 77(3):245-52. doi:10.1023/A:1021899904332
15. Contié S, Voorzanger-Rousselot N, Litvin J, Clézardin P, Garnero P. Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer (2011) 128(2):352-60. doi:10.1002/ijc.25591
16. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn (2000) 218(2):235-59. doi:10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.0.CO;2-G
17. Yoshida T, Matsumoto E, Hanamura N, Kalembeyi I, Katsuta K, Ishihara A, et al. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol (1997) 182(4):421-8. doi:10.1002/(SICI)1096-9896(199708)182:4<421::AID-PATH886>3.3.CO;2-L
18. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer (1997) 73(1):10-5. doi:10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4
19. Mori M, Muramatsu Y, Yamada K, Shrestha P, Takai Y. Intracellular localization of tenascin in squamous cell carcinoma of oral cavity: an immunohistochemical study. Anticancer Res (1996) 16(5B):3075-9.
20. Ilmonen S, Jahkola T, Turunen JP, Muhonen T, Asko-Seljavaara S. Tenascin-C in primary malignant melanoma of the skin. Histopathology (2004) 45(4):405-11. doi:10.1111/j.1365-2559.2004.01976.x
21. Pedretti M, Soltermann A, Arni S, Weder W, Neri D, Hillinger S. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer (2009) 64(1):28-33. doi:10.1016/j.lungcan.2008.07.013
22. Saupe F, Schwenzer A, Jia Y, Gasser I, Spenlé C, Langlois B, et al. Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Rep (2013) 5(2):482-92. doi:10.1016/j.celrep.2013.09.014
23. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 17(7):867-74. doi:10.1038/nm.2379
24. Brellier F, Tucker RP, Chiquet-Ehrismann R. Tenascins and their implications in diseases and tissue mechanics. Scand J Med Sci Sports (2009) 19(4):511-9. doi:10.1111/j.1600-0838.2009.00916.x
25. Didem T, Faruk T, Senem K, Derya D, Murat S, Murat G, et al. Clinical significance of serum tenascin-C levels in epithelial ovarian cancer. Tumour Biol (2014) 35(7):6777-82. doi:10.1007/s13277-014-1923-z
26. Pauli C, Stieber P, Schmitt UM, Andratschke M, Hoffmann K, Wollenberg B. The significance of tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck. Anticancer Res (2002) 22(5):3093-7.
27. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2013) 62(1):112-20. doi:10.1136/gutjnl-2012-302529
28. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. Hyaluronan in human malignancies. Exp Cell Res (2011) 317(4):383-91. doi:10.1016/j.yexcr.2010.11.017
29. Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des (2008) 72(6):455-82. doi:10.1111/j.1747-0285.2008.00741.x
30. Itano N, Kimata K. Mammalian hyaluronan synthases. IUBMB Life (2002) 1(4):195-9. doi:10.1080/15216540214929
31. Heldin P, Basu K, Olofsson B, Porsch H, Kozlova I, Kahata K. Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer. J Biochem (2013) 154(5):395-408. doi:10.1093/jb/mvt085
32. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature (2013) 499(7458):346-9. doi:10.1038/nature12234
33. Delaney MA, Nagy L, Kinsel MJ, Treuting PM. Spontaneous histologic lesions of the adult naked mole rat (Heterocephalus glaber): a retrospective survey of lesions in a zoo population. Vet Pathol (2013) 50(4):607-21. doi:10.1177/0300985812471543
34. Buffenstein R. Negligible senescence in the longest living rodent, the naked mole-rat: insights from a successfully aging species. J Comp Physiol B (2008) 178(4):439-45. doi:10.1007/s00360-007-0237-5
35. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev (2009) 28(1-2):233-45. doi:10.1007/s10555-009-9182-y
36. Evanko SP, Angello JC, Wight TN. Formation of hyaluronan-and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (1999) 19(4):1004-13. doi:10.1161/01.ATV.19.4.1004
37. Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, et al. Formation of hyaluronan-and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem (2007) 282(14):10814-25. doi:10.1074/jbc.M606991200
38. Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK, Ricciardelli C. Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis (2011) 28(2):113-25. doi:10.1007/s10585-010-9363-7
39. Keire PA, Bressler SL, Lemire JM, Edris B, Rubin BP, Rahmani M, et al. A role for versican in the development of leiomyosarcoma. J Biol Chem (2014) 289(49):34089-103. doi:10.1074/jbc.M114.607168
40. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res (1998) 4(4):963-71.
41. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, et al. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res (2002) 8(4):1054-60.
42. Pirinen R, Leinonen T, Böhm J, Johansson R, Ropponen K, Kumpulainen E, et al. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol (2005) 36(1):44-50. doi:10.1016/j.humpath.2004.10.010
43. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer (2012) 12(8):540-52. doi:10.1038/nrc3319
44. Cox TR, Erler JT. The importance of LOX family members on modulating cell-ECM interactions in carcinogenesis. J Carcinog Mutagen (2013) S13:001. doi:10.4172/2157-2518.S13-001
45. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res (2003) 5(5):R129-35. doi:10.1186/bcr622
46. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med (2007) 356(3):227-36. doi:10.1056/NEJMoa062790
47. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med (2008) 6:11. doi:10.1186/1741-7015-6-11
48. Reymond N, d'Água BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer (2013) 13(12):858-70. doi:10.1038/nrc3628
49. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119(6):1420-8. doi:10.1172/JCI39104
50. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev (2010) 29(2):295-307. doi:10.1007/s10555-010-9221-8
51. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 15(3):178-96. doi:10.1038/nrm3758
52. Kultti A, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R, et al. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. Biomed Res Int (2014) 2014:817613. doi:10.1155/2014/817613
53. Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol (2007) 170(3):1086-99. doi:10.2353/ajpath.2007.060793
54. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol (2009) 174(3):1027-36. doi:10.2353/ajpath.2009.080501
55. El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A (2012) 109(43):17460-5. doi:10.1073/pnas.1206653109
56. Hosono K, Nishida Y, Knudson W, Knudson CB, Naruse T, Suzuki Y, et al. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol (2007) 171(1):274-86. doi:10.2353/ajpath.2007.060828
57. McBride WH, Bard JBL. Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med (1979) 149(2):507-15. doi:10.1084/jem.149.2.507
58. Desjardins M, Xie J, Gurler H, Muralidhar GG, Sacks JD, Burdette JE, et al. Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids. J Ovarian Res (2014) 7:70. doi:10.1186/1757-2215-7-70
59. Singleton PA, Dudek SM, Ma SF, Garcia JG. Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem (2006) 281(45):34381-93. doi:10.1074/jbc.M603680200
60. Singleton PA, Mirzapoiazova T, Guo Y, Sammani S, Mambetsariev N, Lennon FE, et al. High-molecular-weight hyaluronan is a novel inhibitor of pulmonary vascular leakiness. Am J Physiol Lung Cell Mol Physiol (2010) 299(5):L639-51. doi:10.1152/ajplung.00405.2009
61. Mambetsariev N, Mirzapoiazova T, Mambetsariev B, Sammani S, Lennon FE, Garcia JG, et al. Hyaluronic acid binding protein 2 is a novel regulator of vascular integrity. Arterioscler Thromb Vasc Biol (2010) 30(3):483-90. doi:10.1161/ATVBAHA.109.200451
62. Lennon FE, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton PA. Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. J Biol Chem (2014) 289(35):24043-58. doi:10.1074/jbc.M114.554766
63. Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res (2006) 66(24):11745-53. doi:10.1158/0008-5472.CAN-06-2322
64. Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res (2006) 66(9):4662-71. doi:10.1158/0008-5472.CAN-05-2804
65. Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, et al. Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res (2013) 73(11):3285-96. doi:10.1158/0008-5472.CAN-12-3963
66. Xiong G, Deng L, Zhu J, Rychahou PG, Xu R. Prolyl-4-hydroxylase a subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer (2014) 14(1):1. doi:10.1186/1471-2407-14-1
67. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell (2009) 139(5):891-906. doi:10.1016/j.cell.2009.10.027
68. Baker AM, Cox TR, Bird D, Lang G, Murray GI, Sun XF, et al. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. J Natl Cancer Inst (2011) 103(5):407-24. doi:10.1093/jnci/djq569
69. Baker AM, Bird D, Lang G, Cox TR, Erler JT. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene (2013) 32(14):1863-8. doi:10.1038/onc.2012.202
70. Barker HE, Bird D, Lang G, Erler JT. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. Mol Cancer Res (2013) 11(11):1425-36. doi:10.1158/1541-7786.MCR-13-0033-T
71. Leight JL, Wozniak MA, Chen S, Lynch ML, Chen CS. Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition. Mol Biol Cell (2012) 23(5):781-91. doi:10.1091/mbc.E11-06-0537
72. Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH, Majeski HE, et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat Cell Biol (2015) 17(5):678-88. doi:10.1038/ncb3157
73. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol (2010) 22(5):697-706. doi:10.1016/j.ceb.2010.08.015
74. Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol (2011) 178(3):1221-32. doi:10.1016/j.ajpath.2010.11.076
75. Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, et al. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol (2013) 15(6):677-87. doi:10.1038/ncb2743
76. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol (2002) 14(5):608-16. doi:10.1016/S0955-0674(02)00361-7
77. Yan W, Shao R. Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Bioll Chem (2006) 281(28):19700-9. doi:10.1074/jbc.M601856200
78. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 141(1):52-67. doi:10.1016/j.cell.2010.03.015
79. Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 70(13):5281-92. doi:10.1158/0008-5472.CAN-10-0704
80. Siriwardena BS, Kudo Y, Ogawa I, Kitagawa M, Kitajima S, Hatano H, et al. Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer (2006) 95(10):1396-403. doi:10.1038/sj.bjc.6603431
81. Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y, et al. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol (2011) 178(2):754-63. doi:10.1016/j.ajpath.2010.10.015
82. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 451(7175):147-52. doi:10.1038/nature06487
83. Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer (2003) 105(1):53-60. doi:10.1002/ijc.11037
84. Nisticò P, Bissell MJ, Radisky DC. Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harbor Perspect Biol (2012) 4(2):a011908. doi:10.1101/cshperspect.a011908
85. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell (1986) 47(1):131-9. doi:10.1016/0092-8674(86)90374-0
86. Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, et al. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer (1998) 78(11):1507-13. doi:10.1038/bjc.1998.714
87. Amo L, Tamayo-Orbegozo E, Maruri N, Eguizabal C, Zenarruzabeitia O, Riñón M, et al. Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1. Front Oncol (2014) 4:1-7. doi:10.3389/fonc.2014.00245
88. Rybarczyk BJ, Simpson-Haidaris PJ. Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Cancer Res (2000) 60(7):2033-9.
89. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci (2001) 936:406-25. doi:10.1111/j.1749-6632.2001.tb03525.x
90. Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov (2012) 2(12):1091-9. doi:10.1158/2159-8290.CD-12-0329
91. Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol (2014) 229(8):1005-15. doi:10.1002/jcp.24539
92. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood (2000) 96(10):3302-9.
93. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood (2004) 104(2):397-401. doi:10.1182/blood-2004-02-0434
94. Malik G, Knowles LM, Dhir R, Xu S, Yang S, Ruoslahti E, et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res (2010) 70(11):4327-34. doi:10.1158/0008-5472.CAN-09-3312
95. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer (2011) 11(2):123-34. doi:10.1038/nrc3004
96. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev (2014) 33(1):231-69. doi:10.1007/s10555-014-9498-0
97. Schaff M, Receveur N, Bourdon C, Wurtz V, Denis CV, Orend G, et al. Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol (2011) 31(1):117-24. doi:10.1161/ATVBAHA.110.206375
98. Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost GI, et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther (2014) 14(2):523-32. doi:10.1158/1535-7163.MCT-14-0580
99. Singleton PA. Hyaluronan regulation of endothelial barrier function in cancer. Adv Cancer Res (2014) 123:191-209. doi:10.1016/B978-0-12-800092-2.00007-1
100. McFarlane S, Coulter JA, Tibbits P, O'Grady A, McFarlane C, Montgomery N, et al. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget (2015) 6(13):11465-76. doi:10.18632/oncotarget.3410
101. Simpson MA, Reiland J, Burger SR, Furcht LT, Spicer AP, Oegema TR Jr, et al. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. J Biol Chem (2001) 276(21):17949-57. doi:10.1074/jbc.M010064200
102. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res (2004) 64(16):5702-11. doi:10.1158/0008-5472.CAN-04-0389
103. Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK, Hirota S, et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res (2012) 72(2):537-47. doi:10.1158/0008-5472.CAN-11-1678
104. Simpson MA, Weigel JA, Weigel PH. Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer. Int J Cancer (2012) 131(5):E836-40. doi:10.1002/ijc.27427
105. Hirose Y, Saijou E, Sugano Y, Takeshita F, Nishimura S, Nonaka H, et al. Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. Proc Natl Acad Sci U S A (2012) 109(11):4263-8. doi:10.1073/pnas.1117560109
106. Wu M, Cao M, He Y, Liu Y, Yang C, Du Y, et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis. FASEB J (2014) 1(4):1-9. doi:10.1096/fj.14-259978
107. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, et al. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) (2012) 90(7):803-15. doi:10.1007/s00109-011-0855-y
108. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 440(7088):1222-6. doi:10.1038/nature04695
109. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 15(1):35-44. doi:10.1016/j.ccr.2008.11.012
110. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res (2013) 73(6):1721-32. doi:10.1158/0008-5472.CAN-12-2233
111. Wong GS, Rustgi AK. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer (2013) 108(4):755-61. doi:10.1038/bjc.2012.592
112. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 9(4):285-93. doi:10.1038/nrc2621
113. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res (2006) 66(19):9339-44. doi:10.1158/0008-5472.CAN-06-3126
114. Rizwan A, Bulte C, Kalaichelvan A, Cheng M, Krishnamachary B, Bhujwalla ZM, et al. Metastatic breast cancer cells in lymph nodes increase nodal collagen density. Sci Rep (2015) 5:10002. doi:10.1038/srep10002
115. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 438(7069):820-7. doi:10.1038/nature04186
116. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res (2012) 72(6):1384-94. doi:10.1158/0008-5472.CAN-11-2905
117. Sheng W, Wang G, La Pierre DP, Wen J, Deng Z, Wong CK, et al. Versican mediates mesenchymal-epithelial transition. Mol Biol Cell (2006) 17(4):2009-20. doi:10.1091/mbc.E05-10-0951
118. Kobayashi N, Miyoshi S, Mikami T, Koyama H, Kitazawa M, Takeoka M, et al. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res (2010) 70(18):7073-83. doi:10.1158/0008-5472.CAN-09-4687
119. Urakawa H, Nishida Y, Knudson W, Knudson CB, Arai E, Kozawa E, et al. Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer. J Orthop Res (2012) 30(4):662-72. doi:10.1002/jor.21557
120. O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA (2011) 108(38):16002-7. doi:10.1073/pnas.1109493108
121. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer (2004) 4(10):806-13. doi:10.1038/nrc1456
122. Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther (2010) 9(11):3052-64. doi:10.1158/1535-7163.MCT-10-0470
123. Brekken C, de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett (1998) 131(1):65-70. doi:10.1016/S0304-3835(98)00202-X
124. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 21(3):418-29. doi:10.1016/j.ccr.2012.01.007
125. Hingorani S, Harris WP, Hendiraf AE, Bullock AJ, Wu XU, Ping J, et al. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: interim results of a randomized phase 2 study. ASCO Annual Meeting (2015). Availble from: http://meetinglibrary.asco.org/content/152325-156
126. Kakizaki I, Kojima K, Takagaki K, Endo M, Kannagi R, Ito M, et al. A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem (2004) 279(32):33281-9. doi:10.1074/jbc.M405918200
127. Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, et al. 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol (2015) 6:123. doi:10.3389/fimmu.2015.00123
128. Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, et al. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Mol Cancer Ther (2013) 12(11):2389-99. doi:10.1158/1535-7163.MCT-13-0132
129. Qhattal HS, Hye T, Alali A, Liu X. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano (2014) 8(6):5423-40. doi:10.1021/nn405839n
130. Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia (2004) 6(4):343-53. doi:10.1593/neo.03460
131. Schmaus A, Klusmeier S, Rothley M, Dimmler A, Sipos B, Faller G, et al. Accumulation of small hyaluronan oligosaccharides in tumour interstitial fluid correlates with lymphatic invasion and lymph node metastasis. Br J Cancer (2014) 111:1-9. doi:10.1038/bjc.2014.332
132. Orecchia P, Conte R, Balza E, Castellani P, Borsi L, Zardi L, et al. Identification of a novel cell binding site of periostin involved in tumour growth. Euro J Cancer (2011) 47(14):2221-9. doi:10.1016/j.ejca.2011.04.026
133. Tai IT, Dai M, Chen LB. Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies. Carcinogenesis (2005) 26(5):908-15. doi:10.1093/carcin/bgi034
134. Lee YJ, Kim IS, Park SA, Kim Y, Lee JE, Noh DY, et al. Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol Ther (2013) 21(5):1004-13. doi:10.1038/mt.2013.30
135. Liu G-X. Role of periostin and its antagonist PNDA-3 in gastric cancer metastasis. World J Gastroenterol (2015) 21(9):2605. doi:10.3748/wjg.v21.i9.2605
136. Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel (2006) 19(10):471-8. doi:10.1093/protein/gzl033
137. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res (1983) 43:2796-805.
138. Lee YS, Bullard DE, Zalutsky MR, Coleman RE, Wikstrand CJ, Friedman HS, et al. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res (1988) 48(3):559-66.
139. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE II, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 20(5):1389-97. doi:10.1200/JCO.20.5.1389
140. Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. Int J Radiat Oncol Biol Phys (2002) 54(4):1259-75. doi:10.1016/S0360-3016(02)03794-X
141. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE II, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol (2008) 10(2):182-9. doi:10.1215/15228517-2007-053
142. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 12(10):3200-8. doi:10.1158/1078-0432.CCR-05-2804
143. Kim MY, Kim OR, Choi YS, Lee H, Park K, Lee CT, et al. Selection and characterization of tenascin C targeting peptide. Mol Cells (2012) 33(1):71-7. doi:10.1007/s10059-012-2214-4
144. Wyszko E, Rolle K, Nowak S, Zukiel R, Nowak M, Piestrzeniewicz R, et al. A multivariate analysis of patients with brain tumors treated with ATN-RNA. Acta Pol Pharm (2008) 65(6):677-84.
145. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med (2010) 16(9):1009-17. doi:10.1038/nm.2208
146. Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E, et al. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Mol Med (2015) 7(8):1063-76. doi:10.15252/emmm.201404827
147. Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes Dis (2015) 2(1):26-34. doi:10.1016/j.gendis.2014.12.002